BIIB 722 CL

DRUG2 trials

Sponsors

Boehringer Ingelheim

Conditions

Healthy

Phase 1

Safety, Tolerability and Pharmacokinetics of Single Rising Doses of BIIB 722 CL and HPβCD in Young Healthy Male Volunteers

CompletedNCT02224079

Boehringer IngelheimHealthy

Start: 2002-04-30Updated: 2014-08-25

Safety, Pharmacodynamics, and Pharmacokinetics After Multiple Different Oral Doses of BIIB 722 CL Tablets in Healthy Volunteers

TerminatedNCT02268604

Boehringer IngelheimHealthy

Start: 2010-10-31Updated: 2014-10-20